Search

Displaying results 9181 - 9190 of 10000 in total
  1. Drug

    Celgosivir

    go.drugbank.com/drugs/DB06580
    Investigational

  2. Drug

    Triphendiol

    go.drugbank.com/drugs/DB06588
    Experimental

  3. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  4. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.

  5. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.

  6. Drug

    Ostabolin-C

    go.drugbank.com/drugs/DB05536
    Investigational

    Ostabolin C was under investigation in clinical trial NCT00787358 (A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT

    Synonyms: -GLUTAMYL-L-ISOLEUCYL-L-GLUTAMINYL-L-LEUCYL-L-METHIONYL-L-HISTIDYL-L-ASPARAGINYL-L-LEUCYLGLYCYL-L-LYSYL-L-HISTIDYL-L-LEUCYL-L-ASPARAGINYL-L-SERYL-L-METHIONYL-L-.ALPHA., L-VALINAMIDE, L-SERYL-L-VALYL-L-SERYL-L-.ALPHA.
  7. Drug

    AVI-4065

    go.drugbank.com/drugs/DB05620
    Investigational

    AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc.

  8. Drug

    MVA-BN-HER-2

    go.drugbank.com/drugs/DB05733
    Experimental

  9. Drug

    AGS-005

    go.drugbank.com/drugs/DB05741
    Experimental

    AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's

  10. Drug

    Tasquinimod

    go.drugbank.com/drugs/DB05861
    Investigational

    The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts